Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction to: Daridorexant: First Approval.

Drugs·2022

Same author

Gefapixant: First Approval.

Drugs·2022

Same author

Daridorexant: First Approval.

Drugs·2022

Same author

Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.

Targeted oncology·2022

Same author

Envafolimab: First Approval.

Drugs·2022

Same author

Correction to: Avatrombopag: A Review in Thrombocytopenia.

Drugs·2021

Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026

Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026

Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026

Same journal

Relacorilant: First Approval.

Drugs·2026

Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026

Same journal

Linerixibat: First Approval.

Drugs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 27, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Siltuximab: first global approval.

Anthony Markham¹, Trina Patel

¹Adis, Auckland, New Zealand.

|June 25, 2014

Summary

This summary is machine-generated.

Siltuximab, an anti-interleukin-6 (IL-6) therapy, is the first approved drug for multicentric Castleman

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Apr 27, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

Immunology
Oncology
Pharmacology

Background:

Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder.
Interleukin-6 (IL-6) plays a critical role in the pathogenesis of MCD.
Limited effective treatment options were available for MCD prior to siltuximab.

Purpose of the Study:

To summarize the key developmental milestones of siltuximab.
To highlight the regulatory approvals for siltuximab in MCD treatment.
To provide an overview of siltuximab's journey to becoming the first approved therapy for MCD.

Main Methods:

Review of preclinical and clinical development data for siltuximab.
Analysis of regulatory submission and approval processes in the US and EU.
Summary of key efficacy and safety findings from pivotal studies.

Main Results:

Siltuximab received FDA approval in the US and CHMP recommendation in the EU for MCD.
The drug demonstrated significant clinical benefit in patients with MCD.
Ongoing development in smoldering multiple myeloma indicates broader therapeutic potential.

Conclusions:

Siltuximab represents a significant therapeutic advancement for MCD patients.
The approval marks a milestone in targeted therapy for rare diseases.
Further research is warranted to explore siltuximab's efficacy in other IL-6-mediated conditions.